ValuEngine cut shares of Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) from a sell rating to a strong sell rating in a research note issued to investors on Monday.
A number of other analysts also recently issued reports on the stock. BidaskClub upgraded shares of Achillion Pharmaceuticals from a strong sell rating to a sell rating in a report on Wednesday, August 16th. Zacks Investment Research downgraded shares of Achillion Pharmaceuticals from a hold rating to a sell rating in a report on Friday, August 11th. Robert W. Baird downgraded shares of Achillion Pharmaceuticals from an outperform rating to a neutral rating and set a $5.00 target price on the stock. in a report on Thursday, August 10th. Maxim Group set a $7.00 target price on shares of Achillion Pharmaceuticals and gave the stock a buy rating in a report on Wednesday, August 9th. Finally, Chardan Capital reduced their target price on shares of Achillion Pharmaceuticals from $5.00 to $4.00 and set a neutral rating on the stock in a report on Wednesday, August 9th. Two analysts have rated the stock with a sell rating, four have given a hold rating and five have assigned a buy rating to the company’s stock. Achillion Pharmaceuticals currently has a consensus rating of Hold and an average target price of $7.69.
Achillion Pharmaceuticals (NASDAQ ACHN) opened at 3.57 on Monday. The company has a 50-day moving average of $4.52 and a 200 day moving average of $4.20. The stock’s market capitalization is $488.58 million. Achillion Pharmaceuticals has a 12 month low of $3.15 and a 12 month high of $9.19.
Achillion Pharmaceuticals (NASDAQ:ACHN) last announced its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.16). During the same quarter in the prior year, the company earned ($0.14) earnings per share. On average, equities research analysts anticipate that Achillion Pharmaceuticals will post ($0.66) earnings per share for the current fiscal year.
TRADEMARK VIOLATION WARNING: This news story was first posted by BBNS and is the property of of BBNS. If you are viewing this news story on another site, it was copied illegally and reposted in violation of international copyright & trademark law. The correct version of this news story can be read at https://baseballnewssource.com/markets/achillion-pharmaceuticals-inc-achn-cut-to-strong-sell-at-valuengine/1634097.html.
Hedge funds have recently added to or reduced their stakes in the stock. Cambridge Investment Research Advisors Inc. boosted its stake in shares of Achillion Pharmaceuticals by 3.6% during the 2nd quarter. Cambridge Investment Research Advisors Inc. now owns 23,130 shares of the biopharmaceutical company’s stock worth $106,000 after purchasing an additional 800 shares during the period. SG Americas Securities LLC boosted its stake in shares of Achillion Pharmaceuticals by 18.6% during the 2nd quarter. SG Americas Securities LLC now owns 26,429 shares of the biopharmaceutical company’s stock worth $121,000 after purchasing an additional 4,144 shares during the period. TradeLink Capital LLC purchased a new position in shares of Achillion Pharmaceuticals during the 2nd quarter worth about $132,000. Teza Capital Management LLC purchased a new position in shares of Achillion Pharmaceuticals during the 1st quarter worth about $131,000. Finally, Dynamic Technology Lab Private Ltd purchased a new position in shares of Achillion Pharmaceuticals during the 1st quarter worth about $138,000. 74.12% of the stock is owned by hedge funds and other institutional investors.
About Achillion Pharmaceuticals
Achillion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drug therapies for infectious diseases and immune system disorders. The Company is focused on its complement inhibitor platform, directed at advancing small molecule compounds that have the potential to be used in the treatment of immune-related diseases associated with the alternative pathway of the complement system.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Achillion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achillion Pharmaceuticals Inc. and related companies with our FREE daily email newsletter.